We had the opportunity to discuss last week about “Multibatching” activity in Pharmaceutical Industry. It’s very common to split some produced batches in different packaged batches according to the quantities demanded of clients and markets. On the other hand, some laboratories have the contrary situation, the need to add some formulated batches and group all of them in only one packaged batch. That’s what is known as “Multibatching”.
Thanks to Rovi Alcalá organization, one of the companies that applies this practice, we could organize another roundtable inside the “Foro of Pharmaceutical Industry” to discuss the benefits and risks of “Multibatching” practice.
We started the meeting discussing about the causes that makes “Multibatching” a good practice to start with (volumes, cycle time, reliability of the process…) and how it should be treated as a business risk instead of quality risk and we followed with different issues that should be considered in case of start with “Multibatching”:
- Which is the administration vision for this practice?
- In which countries is easy to penetrate with “Multibatching” and in which countries it is not allowed to do it.
- Certifications and number of analysis required.
- Track and trace.
- How to manage with SAP.
- Benefits of the “Multibatching” implementation.
As a result of this roundtable, participants interested in this practice got very comfortable to start with this approach. All the questions were absolutely answered and discussed with cases and data. Once again, this kind of pragmatic meetings allow laboratories to share knowledge and experience to start different practices with low risk and good benefits for them.
